The results suggest that AZ and Daiichi Sankyo could be in line for ... Gilead is also testing its drug as a first-line therapy for NSCLC in combination with Keytruda in a trial sponsored by ...

The first patients have been dosed in three global, randomized phase 3 trials evaluating the efficacy and safety of datopotamab deruxtecan (Dato-DXd)- ...

in combination with standard cytarabine/anthracycline induction therapy and cytarabine consolidation therapy for these patients, and as maintenance monotherapy thereafter. Daiichi Sankyo says ...

Daiichi Sankyo & AstraZeneca’s Enhertu receives 2024 Prix Galien USA Award for Best Biotechnology Product: Tokyo Monday, November 11, 2024, 09:00 Hrs [IST] Daiichi Sankyo and As ...

As one of the leading Japanese pharmaceutical companies with headquarters in Europe, Daiichi Sankyo aims to revolutionize ... is shifting toward targeted therapy. This approach, already ...

Quizartinib (Vanflyta, Daiichi Sankyo) is indicated 'in combination with standard cytarabine and anthracycline induction and standard cytarabine consolidation chemotherapy, followed by Vanflyta single ...

In this article, we take a look at eight biotechs that have acquired funding in recent years to fortify their GPCR-focused ...

Oncolytics Biotech is seeking accelerated approval for its lead cancer therapy, pelareorep ... of ADC therapies such as ...

An obvious next step in the development and growth of CAR T-cell therapies has been the jump to solid tumors. Because of ...

Apart from TROPION-Breast01, AstraZeneca and Daiichi Sankyo are conducting assessments of datopotamab deruxtecan as a standalone treatment and in combination with immunotherapy for patients with ...

A phase III trial testing this new combination therapy with UAB as the lead institution showed ... and has received support for this research from Daiichi Sankyo through the UAB/Sankyo Program for ...

Aileen Lamb, from Edinburgh who had acute myeloid leukaemia said the approval of the new drug gives sufferers hope.